Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 6
2004 8
2005 11
2006 5
2007 8
2008 8
2009 13
2010 7
2011 20
2012 20
2013 12
2014 13
2015 14
2016 8
2017 18
2018 13
2019 10
2020 20
2021 26
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

209 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for andreas jung
Search for András Jung instead (1 results)
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.
McClenaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrnes CA, Colombo C, Corvol H, Cheng SY, Daneau G, Elbert A, Faro A, Goss CH, Gulmans V, Gutierrez H, de Monestrol I, Jung A, Justus LN, Kashirskaya N, Marshall BC, McKone E, Middleton PG, Mondejar-Lopez P, Pastor-Vivero MD, Padoan R, Rizvi S, Ruseckaite R, Salvatore M, Stephenson AL, Filho LVRDS, Melo J, Zampoli M, Carr SB; Global Registry Harmonization Group. McClenaghan E, et al. Among authors: jung a. J Cyst Fibros. 2020 Nov;19(6):868-871. doi: 10.1016/j.jcf.2020.10.003. Epub 2020 Nov 4. J Cyst Fibros. 2020. PMID: 33183965 Free PMC article.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: jung a. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.
Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. Kato H, et al. Among authors: jung a. Nature. 2006 May 4;441(7089):101-5. doi: 10.1038/nature04734. Epub 2006 Apr 9. Nature. 2006. PMID: 16625202
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study.
Bain R, Cosgriff R, Zampoli M, Elbert A, Burgel PR, Carr SB, Castaños C, Colombo C, Corvol H, Faro A, Goss CH, Gutierrez H, Jung A, Kashirskaya N, Marshall BC, Melo J, Mondejar-Lopez P, de Monestrol I, Naehrlich L, Padoan R, Pastor-Vivero MD, Rizvi S, Salvatore M, Filho LVRFDS, Brownlee KG, Haq IJ, Brodlie M. Bain R, et al. Among authors: jung a. J Cyst Fibros. 2021 Jan;20(1):25-30. doi: 10.1016/j.jcf.2020.11.021. Epub 2020 Dec 3. J Cyst Fibros. 2021. PMID: 33309057 Free PMC article.
5'-Triphosphate RNA is the ligand for RIG-I.
Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. Hornung V, et al. Among authors: jung a. Science. 2006 Nov 10;314(5801):994-7. doi: 10.1126/science.1132505. Epub 2006 Oct 12. Science. 2006. PMID: 17038590
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. Heinemann V, et al. Among authors: jung a. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6. Br J Cancer. 2021. PMID: 33154570 Free PMC article. Clinical Trial.
The grandfather.
Jung A. Jung A. J Anal Psychol. 2011 Nov;56(5):653-73. doi: 10.1111/j.1468-5922.2011.01938.x. J Anal Psychol. 2011. PMID: 22039946
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators. Stintzing S, et al. Among authors: jung a. Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27. Lancet Oncol. 2016. PMID: 27575024 Clinical Trial.
Liquid Biopsy in Tumor Genetic Diagnosis.
Jung A, Kirchner T. Jung A, et al. Dtsch Arztebl Int. 2018 Mar 9;115(10):169-174. doi: 10.3238/arztebl.2018.0169. Dtsch Arztebl Int. 2018. PMID: 29587961 Free PMC article. Review.
209 results